Short Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Grows By 18.0%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 4,450,000 shares, an increase of 18.0% from the August 31st total of 3,770,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 3.8 days.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at $35,632. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 7,093 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The disclosure for this sale can be found here. Insiders sold a total of 57,491 shares of company stock worth $15,446,733 over the last quarter. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after buying an additional 287,064 shares in the last quarter. Quattro Financial Advisors LLC increased its stake in Alnylam Pharmaceuticals by 2,517.8% in the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after acquiring an additional 4,809 shares during the last quarter. Plato Investment Management Ltd raised its position in Alnylam Pharmaceuticals by 2,666.3% during the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 4,346 shares in the last quarter. SteelPeak Wealth LLC raised its position in Alnylam Pharmaceuticals by 147.7% during the first quarter. SteelPeak Wealth LLC now owns 6,860 shares of the biopharmaceutical company’s stock valued at $1,025,000 after purchasing an additional 4,090 shares in the last quarter. Finally, Diversified Trust Co bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $1,210,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Leerink Partners raised their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday, June 25th. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Needham & Company LLC lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Stifel Nicolaus boosted their price objective on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $279.14.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $274.91 on Friday. The stock has a market cap of $34.77 billion, a P/E ratio of -102.58 and a beta of 0.38. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $287.55. The firm’s fifty day moving average price is $263.00 and its 200-day moving average price is $203.01.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% compared to the same quarter last year. During the same quarter last year, the business posted ($2.21) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals will post -2.73 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.